Genetic modifier HDAC6 was found to control tumor growth and halt metastasis in triple-negative breast cancer in vivo, according to a new study published in the journal Cancer Research by investigators at the GW Cancer Center.
A recent survey from the GW Cancer Center found that enrollment in a supportive oncodermatology program is associated with a significantly improved quality of life score. The results are published in the Journal of Drugs in Dermatology.
WASHINGTON (April 28, 2020) — Skin cancer is one of the most common types of…
GW Cancer Center Expands Clinical Trial Offerings for Patients with High Risk Cutaneous Squamous Cell Carcinoma
The Cutaneous Oncology Program at the GW Cancer Center was selected as the first global site for a clinical trial for patients with high-risk cutaneous squamous cell carcinoma. The study, sponsored by Regeneron, will examine outcomes for patients treated with Libtayo® (cemiplimab) — an immunotherapy treatment — prior to surgery and radiation therapy.
WASHINGTON (Oct. 30, 2019) — November is Lung Cancer Awareness Month and according to the…
WASHINGTON (Sept. 24, 2019) – Breast cancer is the second most commonly diagnosed cancer in…
GW Cancer Center Researchers Find Potential Therapeutic Target for Prostate Cancers with PTEN Mutation
PTEN, a tumor suppressor gene mutated in about 20% of prostate cancers, relies on another gene, ARID4B, to function. These findings were published by George Washington University Cancer Center researchers in Nature Communications.
Researchers at the GW Cancer Center have identified the protein ERK as an important mechanism behind platinum-resistance in platinum-resistant ovarian cancer. The study is published in Clinical Cancer Research.